RMI-L4

RMI-L4 is an efficient cyclic peptide inhibitor that can specifically disrupt the interaction between FANCM and RMI proteins with an IC50 of 54 nM. RMI-L4 engages the FANCM-binding pocket of RMI1/2 with nanomolar affinity (KD = 2.5 nM) . RMI-L4 cannot penetrate the cell membrane and can be used to study the FANCM-RMI pathway targeting cancer with alternate lengthening of telomeres (ALT) [1].

12352209

DNA/RNA Synthesis

Cell Cycle/DNA Damage

Cancer-programmed cell death

Cancer

O=C([C@@H](N1)CC2=CC=C(O)C=C2)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N3[C@H](C(N[C@H](C(N)=O)CSCC1=O)=O)CCC3)=O)[C@H](CC)C)=O)CO)=O)CC4=CC=C(C=C4)O)=O)CC5=CC=C(O)C=C5)=O)CCCCN)=O)CC(O)=O)=O)CC6=CC=CC=C6)=O)CC(C)C)=O)[C@H](CC)C)=O)CO

C80H111N15O21S

1650.89

[1]Cheng W, et al. Discovery of Novel Cyclic Peptides as SMAD2-SMAD4 Interaction Inhibitors for the Treatment of Hepatic Fibrosis. J Med Chem. 2025 May 22;68 (10) :9958-9972.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11224/

Peptides

No Development Reported